Exagen
XGN
27 hedge funds and large institutions have $55.5M invested in Exagen in 2019 Q3 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
29.77% more ownership
Funds ownership: 0% → 29.77% (+30%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$8.26M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.07M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$6.86M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.99M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.87M |
Top Sellers
XGN Hedge Fund Activity: Q3 2019 in Review
27 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q3 2019, worth a combined $55.5M.
Buyers outnumbered sellers: 27 funds opened new XGN positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $8.26M.
- 27 institutional investors held Exagen (XGN) as of Q3 2019, up from 0 in Q2 2019.
- Funds reported $55.5M of Exagen stock for Q3 2019.
- 27 funds opened new Exagen positions in Q3 2019 and 0 closed out, a net change of +27 holders.
- The largest Exagen buyer in Q3 2019 was RTW Investments, an estimated $8.26M added.
Based on aggregated 13F filings for Q3 2019.